Sana Biotechnology Inc Aktie News

Peer‑reviewter Leserbrief beschreibt aktualisierte Langzeitergebnisse, die mit den Anfangsdaten der Zulassungsstudie übereinstimmen, die 2025 im NEJM veröffentlicht wurden

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), ein Unternehmen, das darauf abzielt, durch gentechnisch veränderte Zellen neue Möglichkeiten für Patienten zu schaffen, kündigte heute einen Symposiumsbeitrag an, der klinische Daten aus einer von Untersuchern initiierten, erstmaligen Studie am Menschen präsentiert, bei der UP421, eine allogene primäre Inselzell...

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.

SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company's common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. ...

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in...

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m. PT on Tuesday, May 12, 2026.